ClinicalTrials.Veeva

Menu

Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics

F

Federal University of Vicosa

Status

Completed

Conditions

Overweight
Type 2 Diabetes Mellitus

Treatments

Dietary Supplement: Dietary calcium supplementation
Dietary Supplement: Control

Study type

Interventional

Funder types

Other

Identifiers

NCT02377076
526.005

Details and patient eligibility

About

Dietary calcium seems to act on glycemic control, favoring the prevention and treatment of type 2 diabetes mellitus (DM2). It is possible that calcium modulates gut microbiota and increase the integrity of the intestinal mucosa. This study aims to evaluate the effects of dietary calcium supplementation in permeability and intestinal microbiota in overweight type 2 diabetics. This is a single-blind, randomized, placebo-controlled, crossover study. Patients (n=20) with low habitual calcium intake will be allocated in control group (CONTROL) or test group (DAIRY). Hypocaloric diets (restriction of 500 kcal / day) will be prescribed containing 800 mg of calcium from dietary sources / day. During intervention period, a beverage (shake) (CONTROL - without the addition of calcium sources or DAIRY - 700 mg of calcium as milk powder) will be ingested in the laboratory. Food intake, body composition (total body fat and fat free mass) and anthropometric measures (waist circumference, waist-hip ratio, waist-height, neck circumference and sagittal abdominal diameter) will be evaluated at baseline and at the 6th and 12th weeks. Physical activity level, gut permeability, gut microbiota, and biochemical parameters (parathyroid hormone, 25-dihydroxy vitamin D, calcium, fasting glucose, fasting insulin, fructosamine, hemoglobin, HbA1c, uric acid, triglycerides, cholesterol total and partial, lipopolysaccharide, inflammatory markers) will be evaluated at baseline and after 12 weeks. The statistical analysis will be performed with the use of SPSS software (SPSS Inc., Chicago, IL, 2008, version 17.0). Parametric or non-parametric tests will be applied, according to the distribution of variables (level of statistical significance of 5%).

Enrollment

38 patients

Sex

All

Ages

20 to 59 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Type 2 diabetes mellitus using oral hypoglycemic medication
  • Overweight (body mass index between 25 and 34.9 kg / m2)
  • Usual intake of calcium less than 600 mg / day
  • Level of physical activity light to moderate
  • HbA1c above 7% or fasting glucose above 130 mg / dl

Exclusion criteria

  • Smoking
  • Use of calcium, vitamin D, magnesium, zinc, chromium, copper supplements or medication affecting the metabolism of these micronutrients,
  • Use of drugs, herbs or diets that reduce appetite and body weight
  • Estrogen replacement
  • Gain or loss of at least 5 kg in the last 3 months
  • Recent change in the level of physical activity
  • Aversion or intolerance to food provided in the study
  • Alcohol consumption of more than 2 doses / day (more than 50g ethanol / day)
  • Eating disorders
  • Endocrine disease, renal disease, hepatic disease or malabsorption syndrome that alters calcium metabolism
  • History of recurrent nephrolithiasis
  • Caffeine consumption of> 300 mg / day
  • Pregnancy, lactation or postmenopausal
  • Anemia
  • Cardiovascular, infectious, inflammatory, thyroid, liver, kidney or intestinal disease
  • Use of anti-inflammatory, antacids, antibiotics and laxatives drugs
  • Major gastrointestinal surgery.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

38 participants in 2 patient groups, including a placebo group

DAIRY
Experimental group
Description:
Dietary calcium supplementation
Treatment:
Dietary Supplement: Dietary calcium supplementation
CONTROL
Placebo Comparator group
Description:
Control
Treatment:
Dietary Supplement: Control

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems